BioNTech
NEWS
The designation will provide for an expedited pathway for regulatory review of the preventative medication, which could come later this year.
BioNTech Chief Executive Officer Ugur Sahin predicts the company’s vaccine for COVID-19, which is it co-developing with Pfizer, could be ready for regulatory approval by the end of the year, with hundreds of millions of doses available for immediate distribution.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
Pfizer and BioNTech indicate that this data, along with preclinical data and additional data being generated, will be leveraged to choose a dose level and pick the best vaccine candidate out of the several being evaluated.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 1, 2020.
Clinical-stage biotechnology company BioNTech announced a private investment of $250 million today, led by Temasek and other investors.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 29, 2020.
Less than one month after the White House zeroed in on 14 vaccine candidates for COVID-19, the administration has narrowed that list even more to five potential treatments for the prevention of the novel coronavirus.
JOBS
IN THE PRESS